Integrated Discovery-to-IND Support for Small Molecules, Biologics, ADCs, and Novel Modalities
ChemPartner delivers integrated DMPK and exploratory toxicology services designed to accelerate drug development from lead optimization through IND submission.
Full DMPK and exploratory toxicology, under one roof
Four connected platforms carry your candidate from early ADME profiling to IND-enabling safety — one team, one workflow.
In Vitro ADME
Profile absorption and metabolism early to guide which candidates advance.
Metabolite ID
Map what your compound becomes and how it clears, across every modality.
In Vivo PK & Bioanalysis
Quantify real exposure with high-sensitivity bioanalysis you can act on.
Exploratory Toxicology
Surface safety liabilities before formal GLP toxicology studies begin.
Global scale, decision-ready data
With 300+ scientists and more than 10,000+ m² of laboratory infrastructure, ChemPartner supports global biopharma companies with high-quality DMPK, bioanalysis, Met ID, and exploratory toxicology programs — aligned with FDA, EMA, NMPA, WHO, and ICH expectations.
Standard in vitro ADME studies and many exploratory toxicology assays are typically completed within one week, helping teams make faster decisions without compromising scientific rigor.
SCIENTISTS
M² OF LAB SPACE
ADME TURNAROUND
GLOBAL FRAMEWORKS
Why teams choose ChemPartner
Integrated discovery-to-IND expertise
ChemPartner combines in vitro ADME, bioanalysis, Met ID, formulation sciences, in vivo PK, exploratory toxicology, safety pharmacology, and histopathology in one coordinated framework — streamlining workflows and supporting regulator-ready IND-enabling packages.
Broad Modality Coverage
From small molecules to monoclonal antibodies, ADCs, peptides, oligonucleotides, siRNA, PROTACs, and LNP-based therapeutics — broad experience enabling tailored strategies for complex drug programs.
Fast Turnaround with Global Quality Standards
Automation-enabled workflows, advanced LC-MS technologies, and experienced scientific teams deliver rapid, reliable data aligned with global regulatory expectations.
Core service areas
Four integrated platforms span the full DMPK and exploratory toxicology workflow — from ADME profiling to IND-enabling safety assessment.
Tailored strategies across every modality
Each program receives customized scientific support aligned with modality-specific challenges and regulatory expectations.
Designed to support global IND-enabling programs
Frequently asked questions
What are DMPK services?
DMPK services evaluate how a drug is absorbed, distributed, metabolized, and excreted in biological systems. These studies help predict human pharmacokinetics and optimize drug candidates before clinical trials.
What is exploratory toxicology?
Exploratory toxicology involves early-stage safety studies designed to identify potential toxicities before formal GLP toxicology testing begins.
Can ChemPartner support biologics and ADCs?
Yes. ChemPartner supports biologics, ADCs, peptides, oligonucleotides, and other complex therapeutic modalities across DMPK, bioanalysis, Met ID, and exploratory toxicology workflows.
How quickly can studies be completed?
Many standard in vitro ADME and exploratory toxicology studies are completed within approximately one week, depending on scope and complexity.
Does ChemPartner support IND-enabling programs?
Yes. ChemPartner supports integrated discovery-to-IND programs with DMPK, toxicology, bioanalysis, and regulatory-aligned scientific support.
What analytical technologies are used?
ChemPartner utilizes advanced LC-MS/MS systems, high-resolution mass spectrometry, ligand-binding assays, and automation-enabled workflows to support high-quality data generation.
Accelerate your discovery-to-IND program
Whether you are optimizing a lead candidate or preparing for IND submission, ChemPartner delivers integrated DMPK and exploratory toxicology services designed to help you move faster with greater confidence.
